Warning – H1N1 Vaccine Risks & Dangers in Canada and the U.S.

---

Canada:

The H1N1 vaccine being used in Canada is Arepanrix H1N1 by GlaxoSmithKline.

“Health Canada has authorized the sale of Arepanrix™ H1N1 based on limited clinical testing in humans under the provision of an Interim Order (IO) issued on October 13, 2009 “

Health Canada – H1N1 vaccine product insert information

On the basis of H1N1 vaccine clinical studies, there is no scientific evidence confirming the long-term safety and effectiveness of Arepanrix. Despite this, The Minister of Health authorized its use, and it is to be used nation-wide.

–

Significant substances

The following, taken from Health Canada’s Arepanrix insert information, lists Antigen and Adjuvants contained in the vaccine:

“Antigen:
…
Preservative content is 5µg Thimerosal USP per 0.5mL dose or 2.5 micrograms organic mercury (Hg) per 0.5mL dose

Adjuvant:
DL-α-tocopherol 11.86 milligrams/0.5mL dose
Squalene 10.69 milligrams/0.5mL dose
Polysorbate 80 4.86 milligrams/0.5mL dose”

(Take notice of Thimerosal and Squalene, both highly toxic substances)

“List of Excipients

Antigen suspension vial: Thimerosal, sodium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, water for injections. The drug substance contains trace residual amounts of egg proteins, formaldehyde, sodium deoxycholate and sucrose.

Adjuvant emulsion vial: sodium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, water for injections.”

–

The following are known dangers of some of the dangerous substances contained in the H1N1 vaccine:

Formaldehyde: This substance is ranked as a very hazardous compounds (worst 10%) to ecosystems and human health. Laboratory animals exposed to doses of inhaled formaldehyde over their lifetimes have developed more cancers than are usual, as have workers in particle-board sawmills.

Sodium Deoxycholate : This substance has been shown to weaken the blood-brain-barrier (BBB) and can subsequently activate seizures and produce other brain-related problems.

Thimerosal: As mercury, known issues include the altered functioning of critical neurotransmitters necessary for proper brain functioning. It is associated to brain neuron degeneration, and inoculation of it can lead to neurological disorders.

Squalene (in AS03 adjuvant): Oil adjuvants like squalene have been ordinarily used to inflict diseases in animals – for experimentation and study. In a 2000 article of The American Journal of Pathology a published study demonstrated that a single injection of the adjuvant squalene into rats triggered a chronic, immune-mediated joint-specific inflammation.
Squalene is not officially licensed for use in the United States or Canada.

Anthrax vaccination laced with squalene led to disastrous consequences, such as cases of Gulf War Syndrome.

The AS03 adjuvant in the Arepanrix H1N1 vaccine contains 10.69mg per dose. This is one million times more squalene per dose than the anthrax vaccine.

–

ADDITIONAL RISKS

( Arepanrix H1N1 vaccine product information — Post-Marketing Surveillance section)

“… the following additional adverse events have been reported:

Blood and lymphatic system disorders
Transient thrombocytopenia.

Immune system disorders
Allergic reactions, in rare cases leading to shock.

Nervous system disorders
Neuralgia, convulsions.
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome.

Vascular disorders
Vasculitis with transient renal involvement.

Skin and subcutaneous tissue disorders
Generalised skin reactions including urticaria”

(Take notice of Guillain Barré syndrome)

–

Guillain-Barré syndrome(GBS) is a known disorder that was also linked to the 1976 swine influenza vaccine.

GBS is an autoimmune disorder affecting the peripheral nervous system, usually triggered by an acute infectious process. It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. (Wikipedia link)

–

Many health concerns regarding the vaccine have not been evaluated, such as carcinogenic / mutagenic potential, or impairment of fertility — this is even stated in the product insert information. Another issue not evaluated is pharmacokinetics(the study of bodily absorption, distribution, metabolism and excretion of ingredients) in order to determine the human body’s capacity for eliminating toxic substances contained in the vaccine.

–

Despite the many known and potential dangers, Canada is proceding with its vaccination campaign. The popular media and most government officials continue to promote the H1N1 vaccine, and insufficient /inadequate attention is brought upon the risks.

–

United States:

The H1N1 vaccine in the U.S. is by Novartis — Influenza A (H1N1) 2009 Monovalent Vaccine.
The vaccine, also, contains Thimerosal and Squalene.

Product information can be found here (Food and Drug Administration site)

–

Here is a list of dangers taken from the Novartis product insert:

“ Body as a whole:  Local injection site reactions (including pain, pain limiting limb movement, redness, swelling, warmth, ecchymosis, induration), hot flashes/flushes; chills; fever; malaise; shivering; fatigue; asthenia; facial edema.

Immune system disorders: Hypersensitivity reactions (including throat and/or mouth edema). In rare cases, hypersensitivity reactions have lead to anaphylactic shock and death.

Cardiovascular disorders: Vasculitis (in rare cases with transient renal involvement), syncope shortly after vaccination.

Digestive disorders: Diarrhea; nausea; vomiting; abdominal pain.

Blood and lymphatic disorders: Local lymphadenopathy; transient thrombocytopenia.

Metabolic and nutritional disorders: Loss of appetite.

Musculoskeletal: Arthralgia; myalgia; myasthenia.

Nervous system disorders: Headache; dizziness; neuralgia; paraesthesia; confusion; febrile convulsions; Guillain-Barré Syndrome; myelitis (including encephalomyelitis and transverse myelitis); neuropathy (including neuritis); paralysis (including Bell’s Palsy).

Respiratory disorders: Dyspnea; chest pain; cough; pharyngitis; rhinitis.

Skin and appendages: Stevens-Johnson syndrome; sweating; pruritus; urticaria; rash (including non-specific, maculopapular, and vesiculobulbous).”

“Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported.”

“Microscopic polyangiitis (vasculitis) has been reported temporally associated with influenza vaccination. “

–

Other Notable information from the Novartis H1N1 vaccine package insert:

“Pregnancy
Pregnancy Category C: Animal reproduction studies have not been conducted with Influenza A (H1N1) 2009 Monovalent Vaccine or FLUVIRIN. It is also not known whether Influenza A (H1N1) 2009 Monovalent Vaccine or FLUVIRIN can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Influenza A (H1N1) 2009 Monovalent Vaccine should be given to a pregnant woman only if clearly needed.”

“Limitations of Vaccine Effectiveness
Vaccination with Influenza A (H1N1) 2009 Monovalent Vaccine may not protect all individuals. “

The information regarding pregnancy is especially concerning, as pregnant women are among the group prioritized, by health officials and the like, in taking the H1N1 vaccine.

–

The H1N1 vaccine is strongly promoted in the United States, by industries and government, with inadequate coverage on risks.

–

In order to assure that the population is aware of the risks and make an informed decision, it is important to share and distribute this information. You can E-mail the link to this post, or even print the vaccine package insert information found on the official Health Authority sites to show around.